← Back to patent-cliff list
Hosu-53
Tier C — Watch / tradeHosu-53
Ohio State University Comprehensive Cancer Center
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DHODH
Indications (approved)：Non-Hodgkin lymphoma, Small cell lung cancer, Solid tumour
Regional status
US
Phase II
2024-09-16
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Hosu-53?
Approved indications include: Non-Hodgkin lymphoma, Small cell lung cancer, Solid tumour.
When does the Hosu-53 patent expire?
No public expiry year is available for Hosu-53 yet; this page updates once verified.
How do I get a quote for Hosu-53 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01